# US 10,500,193 B2 · Combination therapy of HSP90 inhibitors with platinum-containing agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,193 B2
- Document ID: US10500193B2
- Status: Granted
- Kind: B2
- Application number: 15/940,055
- Filed: 2018-03-29
- Published: 2018-08-09
- Granted: 2019-12-10
- Earliest claimed: 2011-11-02
- Assignees: Synta Pharmaceuticals Corp.
- Applicants: Synta Pharmaceuticals Corp.
- Inventors: David Proia
- Web page: https://patentgrep.com/patent/US10500193B2

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61K 31/282: Platinum compounds
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.

## Claims

### Claim 1

A method of treating cancer, wherein the cancer is breast cancer, gastric cancer, colorectal cancer, pancreatic cancer, ocular melanoma, prostate cancer, gastrointestinal stromal tumors (GIST), advanced esophagogastric cancer, melanoma, hepatocellular cancer, solid tumor, liver cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, testicular tumor, ovarian cancer, lymphoma, leukemia, multiple myeloma, or colon cancer, comprising administering to the subject (a) an effective amount of an Hsp90 inhibitor, wherein the Hsp90 inhibitor is selected from the group consisting of 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4] triazole or a tautomer or a pharmaceutically acceptable salt thereof and 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and (b) a platinum-containing anti-cancer agent, wherein the platinum-containing anticancer agent is selected from the group consisting of cisplatin, carboplatin, and oxaliplatin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is gastric cancer, bladder cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, or colorectal cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method comprising administering a compound of 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4] triazole, or a tautomer or a pharmaceutically acceptable salt thereof, and cisplatin.

### Claim 4 (depends on 3)

The method of claim 3, wherein cisplatin is administered at a dose from about 20 mg/m2 to about 150 mg/m2.

### Claim 5 (depends on 3)

The method of claim 3, wherein the amount of the triazole compound is from about 2 mg/m2 to about 260 mg/m2.

### Claim 6 (depends on 5)

The method of claim 5, wherein the amount of the triazole compound is about 75 mg/m2, about 85 mg/m2, about 100 mg/m2, about 110 mg/m2, about 115 mg/m2, about 120 mg/m2, about 145 mg/m2, about 150 mg/m2, about 175 mg/m2, about 180 mg/m2, about 200 mg/m2, about 215 mg/m2 or about 260 mg/m2.

### Claim 7 (depends on 5)

The method of claim 5, wherein the Hsp90 inhibitor is administered IV once weekly or twice weekly.